BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

21 related articles for article (PubMed ID: 3708159)

  • 1. Transglutaminase-catalyzed crosslinking of the Aalpha and gamma constituent chains in fibrinogen.
    Murthy SN; Wilson JH; Lukas TJ; Veklich Y; Weisel JW; Lorand L
    Proc Natl Acad Sci U S A; 2000 Jan; 97(1):44-8. PubMed ID: 10618368
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Photo-oxidation of histidine as a probe for aminoterminal conformational changes during fibrinogen-fibrin conversion.
    Henschen-Edman AH
    Cell Mol Life Sci; 1997 Jan; 53(1):29-33. PubMed ID: 9117995
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Surgical treatment of two patients with asymptomatic hereditary abnormal fibrinogen].
    Luo ML; Yan J; Lin FQ; Cheng P; Deng DH
    Zhonghua Xue Ye Xue Za Zhi; 2017 Sep; 38(9):797-798. PubMed ID: 29081199
    [No Abstract]   [Full Text] [Related]  

  • 4. Identification of novel mutations in patients with fibrinogen disorders and genotype/phenotype correlations.
    Chinni E; Tiscia G; Favuzzi G; Cappucci F; Malcangi G; Bagna R; Izzi C; Rizzi D; De Stefano V; Grandone E
    Blood Transfus; 2019 May; 17(3):247-254. PubMed ID: 30418131
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structure and function of human fibrinogen inferred from dysfibrinogens.
    Matsuda M; Sugo T
    Int J Hematol; 2002 Aug; 76 Suppl 1():352-60. PubMed ID: 12430881
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fibrinogen brescia: hepatic endoplasmic reticulum storage and hypofibrinogenemia because of a gamma284 Gly-->Arg mutation.
    Brennan SO; Wyatt J; Medicina D; Callea F; George PM
    Am J Pathol; 2000 Jul; 157(1):189-96. PubMed ID: 10880389
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fibrinogen Stony Brook, a heterozygous A alpha 16Arg----Cys dysfibrinogenemia. Evaluation of diminished platelet aggregation support and of enhanced inhibition of fibrin assembly.
    Galanakis DK; Henschen A; Peerschke EI; Kehl M
    J Clin Invest; 1989 Jul; 84(1):295-304. PubMed ID: 2738154
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characterization of fibrinogen Milano I: amino acid exchange gamma 330 Asp----Val impairs fibrin polymerization.
    Reber P; Furlan M; Rupp C; Kehl M; Henschen A; Mannucci PM; Beck EA
    Blood; 1986 Jun; 67(6):1751-6. PubMed ID: 3708159
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fibrinogen Bern I: substitution gamma 337 Asn-->Lys is responsible for defective fibrin monomer polymerization.
    Steinmann C; Reber P; Jungo M; Lämmle B; Heinemann G; Wermuth B; Furlan M
    Blood; 1993 Oct; 82(7):2104-8. PubMed ID: 8400260
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fibrinogen Milano XII: a dysfunctional variant containing 2 amino acid substitutions, Aalpha R16C and gamma G165R.
    Bolliger-Stucki B; Lord ST; Furlan M
    Blood; 2001 Jul; 98(2):351-7. PubMed ID: 11435303
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fibrinogen Milano. VI: A heterozygous dysfibrinogenemia (A alpha 16 Arg----His) with bleeding tendency.
    Bögli C; Cofrancesco E; Cortellaro M; Della Volpe A; Hofer A; Furlan M; Zanussi C
    Eur J Haematol; 1990 Jul; 45(1):26-30. PubMed ID: 2379562
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterization of an apparently lower molecular weight gamma-chain variant in fibrinogen Kyoto I. The replacement of gamma-asparagine 308 by lysine which causes accelerated cleavage of fragment D1 by plasmin and the generation of a new plasmin cleavage site.
    Yoshida N; Terukina S; Okuma M; Moroi M; Aoki N; Matsuda M
    J Biol Chem; 1988 Sep; 263(27):13848-56. PubMed ID: 2971046
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fibrinogen St. Gallen I (gamma 292 Gly--> Val): evidence for structural alterations causing defective polymerization and fibrinogenolysis.
    Stucki B; Schmutz P; Schmid L; Haeberli A; Lämmle B; Furlan M
    Thromb Haemost; 1999 Feb; 81(2):268-74. PubMed ID: 10064005
    [TBL] [Abstract][Full Text] [Related]  

  • 14.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 15.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 2.